Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.

Infliximab levels below 6.8 μg/mL and antibodies to infliximab levels above 4.3 μg/mL-eq before the second infusion are associated with primary nonresponse, especially among Crohn's disease patients.